PT  - JOURNAL ARTICLE
AU  - Hartner, Anna-Maria
AU  - Li, Xiang
AU  - Gaythorpe, Katy
TI  - COVID-19-related disruption and resiliency in immunisation activities in LMICs: a rapid review
AID  - 10.1101/2023.06.12.23291133
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.06.12.23291133
4099  - http://medrxiv.org/content/early/2023/06/12/2023.06.12.23291133.short
4100  - http://medrxiv.org/content/early/2023/06/12/2023.06.12.23291133.full
AB  - Objectives Rapid review to determine the extent that immunisation services in LMICs were disrupted by the COVID-19 pandemic and what factors can be considered to build resilience in future.Setting We searched PubMed on 28th Feb 2023 for studies published after 1st December 2019 in English that focused on LMICs.Participants Screening and data extraction were conducted by two experienced reviewers with one reviewer vote minimum per study per stage. Of 3801 identified studies, 66 met the eligibility criteria.Outcomes Routine vaccine coverage achieved; Supplementary immunisation activity timing; Vaccine doses given; Timing of vaccination; Supply chain changes; factors contributing to disruption or resilience.Results Included studies showed evidence of notable declines in immunisation activities across LMICs related to the COVID-19 pandemic. These have included reductions in achieved routine coverage, cancellation or postponement of campaigns, and underimmunised cohorts. Immunisation was most disrupted in the early months of the pandemic, particularly March to May 2020; however, the amount of recovery seen varied by country, age-group, and vaccine. Though many countries observed partial recovery beginning after lockdown policies were lifted in 2020, disruption in many countries has also continued into 2021. It has also been noted that clinician staff shortages and vaccine stock outs caused by supply chain disruptions contributed to immunisation delays but that concern over COVID transmission was a leading factor. Key resiliency factors included community outreach and healthcare worker support. Finally, whilst our search took place in February 2023, the latest dataset used across all studies was from November 2022 and many focused on 2020; as a result some of the study conclusions do not take recovery into account.Conclusions There is limited information on whether reductions in vaccination coverage or delays have persisted beyond 2021. Further research is needed to assess ongoing disruptions and identify missed vaccine cohorts.Strengths and limitations of this studyThe rapid synthesis of findings related to immunization disruption and recovery to-date allows for key insights to target missed cohorts and identify research gaps.We include a narrative analysis of disruption across LMICs; this review benefits from the inclusion of barriers, enablers, and resilience to/in service provision.The search strategy was limited to studies published on PubMed up to February 28th, 2023, meaning not all relevant research meeting inclusion criteria may have been captured.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was carried out as part of the Vaccine Impact Modelling Consortium (www.vaccineimpact.org), which is jointly funded by the Bill & Melinda Gates Foundation (Grant Numbers INV-034281 and INV-009125 / OPP1157270) and Gavi, the Vaccine Alliance. The views expressed are those of the authors and not necessarily those of the Consortium or its funders. The funders were given the opportunity to review this paper prior to publication, but the final decision on the content of the publication was taken by the authors. AMH, XL, and KAMG also acknowledge funding from the MRC Centre for Global Infectious Disease Analysis (reference MR/R015600/1), jointly funded by the UK Medical Research Council (MRC) and the UK Foreign, Commonwealth Development Office (FCDO), under the MRC/FCDO Concordat agreement and is also part of the EDCTP2 programme supported by the European Union; and acknowledge funding by Community Jameel.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript.